Skip to main content
Premium Trial:

Request an Annual Quote

Verinata Health Moves into Larger Facility with Initial Annual Capacity of 150K Tests


This article was originally published Dec. 12.

Verinata Health said last week that is has relocated its corporate headquarters and laboratory to a "much larger" facility in Redwood City, Calif.

The move comes as the company prepares to launch in the first quarter of 2012 a next-generation sequencing-based non-invasive prenatal test for multiple chromosomal abnormalities. According to CEO Caren Mason, the new facility demonstrates the firm's "commitment to appropriately prepare for the growth and expansion expected with the launch" of the test.

The new clinical laboratory has an initial capacity of 150,000 tests per year, and the firm's R&D laboratory has been expanded "substantially," according to the company. Space is available for both laboratories to grow further in the future.

Verinata raised about $46.5 million in a Series C financing round this summer. This fall, the company said it has settled on the Illumina HiSeq 2000 as a platform for its test.

Verinata's test is expected to compete with Sequenom's MaterniT21 test for Down syndrome, which Sequenom launched this fall (CSN 10/19/2011), also using the Illumina HiSeq platform. Both firms claim IP rights to the underlying technology (CSN 9/7/2011).

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.